AgingResearch.NewsJoin free

AAV9-IGFBP7

AAV9-IGFBP7 has been studied in 1 paper since 2024: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Jul 11, 2024: “Vaccine Therapy for Heart Failure Targeting the Inflammatory Cytokine Igfbp7”.

Intervention

1 paper studies it1 findingUpdated

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funder: Japan Society for the Promotion of Science
  • 1 of 1 finding with company ties
  • Animals1

What did studies of AAV9-IGFBP7 find?

1

Studies of AAV9-IGFBP7 measured 1 outcome; the most studied are cardiac dysfunction (1 study).

Cardiac dysfunction

upin mice1

1 study

  1. AAV9-IGFBP7 increases cardiac dysfunction in mice.

    “Overexpression of Igfbp7 in the murine heart using AAV9 (adeno-associated virus serotype 9) exacerbated cardiac dysfunction”

    Animalsin murine heart

    Vaccine Therapy for Heart Failure Targeting the Inflammatory Cytokine Igfbp7

    Circulation

Latest

Related